La Marca, a retired professor living in Basking Ridge, New Jersey, is among an estimated 5.9 million Medicare enrollees excluded from a GLP-1 discount program because they have a medical condition such as Type 2 diabetes or sleep apnea. (Erica S. Lee for KFF Health News)A Temporary Patch for a Long-Standing Gap About 1 in
For roughly 40% of American adults living with obesity, the medical playbook has barely changed in decades: Eat less, move more, and if that fails, wait until the disease progresses far enough to justify surgery. GLP-1 drugs like Ozempic, Wegovy, and Zepbound have broken that script—but according to Robin Wenzel, head of Wells Fargo Industry
Weight-loss drugs are becoming a popular employee perk, with almost a third of workers saying they’d switch jobs to get GLP-1 coverage. Now, Bank of America is spending $250 million or more yearly on the drugs for its staffers—and CEO Brian Moynihan says the upsides are well-worth the eye-watering cost. “What we see is a
